Structural imaging and Parkinson's disease

Moving toward quantitative markers of disease progression

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Parkinson s disease (PD) is a progressive age-related neurodegenerative disorder. Although the pathological hallmark of PD is dopaminergic cell death in the substantia nigra pars compacta, widespread neurodegenerative changes occur throughout the brain as disease progresses. Postmortem studies, for example, have demonstrated the presence of Lewy pathology, apoptosis, and loss of neurotransmitters and interneurons in both cortical and subcortical regions of PD patients. Many in vivo structural imaging studies have attempted to gauge PD-related pathology, particularly in gray matter, with the hope of identifying an imaging biomarker. Reports of brain atrophy in PD, however, have been inconsistent, most likely due to differences in the studied populations (i.e. different disease stages and/or clinical subtypes), experimental designs (i.e. cross-sectional vs. longitudinal), and image analysis methodologies (i.e. automatic vs. manual segmentation). This review attempts to summarize the current state of gray matter structural imaging research in PD in relationship to disease progression, reconciling some of the differences in reported results, and to identify challenges and future avenues.

Original languageEnglish (US)
Pages (from-to)557-567
Number of pages11
JournalJournal of Parkinson's Disease
Volume6
Issue number3
DOIs
StatePublished - Jan 1 2016

Fingerprint

Parkinson Disease
Disease Progression
Pathology
Brain Diseases
Interneurons
Neurodegenerative Diseases
Atrophy
Neurotransmitter Agents
Cell Death
Research Design
Biomarkers
Apoptosis
Brain
Research
Population
Gray Matter

All Science Journal Classification (ASJC) codes

  • Clinical Neurology
  • Cellular and Molecular Neuroscience

Cite this

@article{986d79d9ec30430fa2015db79991b102,
title = "Structural imaging and Parkinson's disease: Moving toward quantitative markers of disease progression",
abstract = "Parkinson s disease (PD) is a progressive age-related neurodegenerative disorder. Although the pathological hallmark of PD is dopaminergic cell death in the substantia nigra pars compacta, widespread neurodegenerative changes occur throughout the brain as disease progresses. Postmortem studies, for example, have demonstrated the presence of Lewy pathology, apoptosis, and loss of neurotransmitters and interneurons in both cortical and subcortical regions of PD patients. Many in vivo structural imaging studies have attempted to gauge PD-related pathology, particularly in gray matter, with the hope of identifying an imaging biomarker. Reports of brain atrophy in PD, however, have been inconsistent, most likely due to differences in the studied populations (i.e. different disease stages and/or clinical subtypes), experimental designs (i.e. cross-sectional vs. longitudinal), and image analysis methodologies (i.e. automatic vs. manual segmentation). This review attempts to summarize the current state of gray matter structural imaging research in PD in relationship to disease progression, reconciling some of the differences in reported results, and to identify challenges and future avenues.",
author = "Sterling, {N. W.} and Mechelle Lewis and Guangwei Du and Xuemei Huang",
year = "2016",
month = "1",
day = "1",
doi = "10.3233/JPD-160824",
language = "English (US)",
volume = "6",
pages = "557--567",
journal = "Journal of Parkinson's Disease",
issn = "1877-7171",
publisher = "IOS Press",
number = "3",

}

Structural imaging and Parkinson's disease : Moving toward quantitative markers of disease progression. / Sterling, N. W.; Lewis, Mechelle; Du, Guangwei; Huang, Xuemei.

In: Journal of Parkinson's Disease, Vol. 6, No. 3, 01.01.2016, p. 557-567.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Structural imaging and Parkinson's disease

T2 - Moving toward quantitative markers of disease progression

AU - Sterling, N. W.

AU - Lewis, Mechelle

AU - Du, Guangwei

AU - Huang, Xuemei

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Parkinson s disease (PD) is a progressive age-related neurodegenerative disorder. Although the pathological hallmark of PD is dopaminergic cell death in the substantia nigra pars compacta, widespread neurodegenerative changes occur throughout the brain as disease progresses. Postmortem studies, for example, have demonstrated the presence of Lewy pathology, apoptosis, and loss of neurotransmitters and interneurons in both cortical and subcortical regions of PD patients. Many in vivo structural imaging studies have attempted to gauge PD-related pathology, particularly in gray matter, with the hope of identifying an imaging biomarker. Reports of brain atrophy in PD, however, have been inconsistent, most likely due to differences in the studied populations (i.e. different disease stages and/or clinical subtypes), experimental designs (i.e. cross-sectional vs. longitudinal), and image analysis methodologies (i.e. automatic vs. manual segmentation). This review attempts to summarize the current state of gray matter structural imaging research in PD in relationship to disease progression, reconciling some of the differences in reported results, and to identify challenges and future avenues.

AB - Parkinson s disease (PD) is a progressive age-related neurodegenerative disorder. Although the pathological hallmark of PD is dopaminergic cell death in the substantia nigra pars compacta, widespread neurodegenerative changes occur throughout the brain as disease progresses. Postmortem studies, for example, have demonstrated the presence of Lewy pathology, apoptosis, and loss of neurotransmitters and interneurons in both cortical and subcortical regions of PD patients. Many in vivo structural imaging studies have attempted to gauge PD-related pathology, particularly in gray matter, with the hope of identifying an imaging biomarker. Reports of brain atrophy in PD, however, have been inconsistent, most likely due to differences in the studied populations (i.e. different disease stages and/or clinical subtypes), experimental designs (i.e. cross-sectional vs. longitudinal), and image analysis methodologies (i.e. automatic vs. manual segmentation). This review attempts to summarize the current state of gray matter structural imaging research in PD in relationship to disease progression, reconciling some of the differences in reported results, and to identify challenges and future avenues.

UR - http://www.scopus.com/inward/record.url?scp=84983732292&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983732292&partnerID=8YFLogxK

U2 - 10.3233/JPD-160824

DO - 10.3233/JPD-160824

M3 - Review article

VL - 6

SP - 557

EP - 567

JO - Journal of Parkinson's Disease

JF - Journal of Parkinson's Disease

SN - 1877-7171

IS - 3

ER -